Emmanuelle Charpentier

A team of researchers at the Innovative Genomics Institute, or IGI, have found a way to use CRISPR technology to edit genes within a community, spearheading huge advancements in the medical industry.

Jennifer Doudna, UC Berkeley professor of chemistry, biochemistry and molecular biology, was awarded half of the Nobel Prize in chemistry Wednesday for developing the gene-editing technology CRISPR-Cas9.

UC Berkeley professor of molecular and cell biology and of chemistry Jennifer Doudna has been awarded the 2020 Wolf Prize in Medicine for her discovery of CRISPR-Cas9 gene-editing tool.

The United States Patent and Trademark Office issued the UC system's 20th CRISPR-Cas9 gene-editing technology patent with the arrival of the new year, according to a press release by Berkeley News.

The UC system was awarded a patent Tuesday, marking the university's 16th patent for the CRISPR-Cas9 patent portfolio — the highest number in the country.

The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology. 

By the end of the summer, the UC system expects to receive five more patents, raising its portfolio to 15 total patents related to CRISPR technology.

The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.

On April 23, the U.S. Patent and Trademark Office issued UC Berkeley its fourth patent for CRISPR Cas-9, a revolutionary gene-editing technology.

After four years of litigation battles, the US Patent and Trademark Office, or USPTO, has finally approved a third CRISPR patent for the University of California.